Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Generic Drug User Fee Amendments

Generic Drug User Fee Amendments

                        GDUFA III Reauthorization
          GDUFA III Enhancements to the Pre-ANDA Program
          ANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
          GDUFA III Controlled Correspondence Enhancements
          GDUFA III Drug Master File (DMF) Review Enhancements
          GDUFA III Changes for Facilities
          GDUFA III User Fee Resource Management Program Home
          For Industry
          FDA User Fee Programs
          Generic Drug User Fee Amendments
          GDUFA II Videos and ResourcesGeneric Drug User Fee Amendments GDUFA II Videos and Resources
  
  	
    Share
    Post
    Linkedin

    Email
    PrintIncreasing consumer access to safe high-quality and affordable generic drugs is a top priority at FDA. In recent years, with the help of user fees from industry and the traditional budget appropriations received from Congress, FDA has approved record numbers of generic drug applications.  The Generic Drug User Fee Amendments (GDUFA) were reauthorized and signed into law by the President on August 18, 2017. The reauthorization, known as GDUFA II, is in effect from October 1, 2017 through September 30, 2022.

In brief videos on this page, FDA staff highlight user fees and the new features in GDUFA II.

GDUFA by Dr. Kathleen “Cook” Uhl, Director, Office of Generic Drugs

In this video, Dr. Uhl shares a brief history of why generic drug user fees came to be, how user fees help the FDA and Industry, accomplishments in GDUFA I, and the features of GDUFA II. The 8 minute 39 second GDUFA video is broken into five segments or you can watch it in its entirety.



GDUFA (8:39)Introduction: About GDUFA (2:49)Why Generic Drug User Fees? (1:09)How FDA Uses Fees (1:22)GDUFA I Accomplishments (1:08)Features of GDUFA II (2:10)

GDUFA II Features

GDUFA Overview
	Pre-ANDA Program for Complex Products
	Type II Drug Master Files (DMF) Update
	Performance Goals
	Goals Integration
	Review Status Updates
	Post Complete Response Letter (CRL) Meeting
	Requests for Reconsideration
	Review ClassificationPre-ANDA Program for Complex Products in GDUFA II

Learn about the three types of meetings for ANDA applicants seeking to develop generic versions of complex products: Product development meetings, Pre-submission meetings, and Mid-review cycle meetings.

Product Development Meetings

Video | Transcript | Slides (PDF - 120KB)

Pre-Submission Meetings

Video | Transcript | Slides (PDF - 117KB)

Mid-Review Cycle Meetings

Webinar | Slides (PDF - 252KB)

Type II Drug Master Files (DMF) Update

This presentation covers changes and new features related to Type II DMFs for Active Pharmaceutical Ingredients (API).

Video | Transcript | Slides (PDF - 126KB)

**Performance Goals**

Review important review goal dates in GDUFA II, what you need to know if you are an FDA reviewer or applicant, and what to expect during review cycles.

Video | Transcript | Slides (PDF - 134KB)

Goals Integration

Review how the new goal structure, review classification process, information requests (IRs), discipline review letters (DRLs), and mid-review cycle meetings are operationalized in GDUFA II.

Video | Transcript | Slides (PDF - 217KB) | Review Definitions (PDF - 90KB)

Review Status Updates

This presentation describes the process for requesting and receiving status updates through the ANDA review process in GDUFA II.

Video | Transcript | Slides (PDF - 309KB)

Post Complete Response Letter Meetings

This presentation outlines the step-by-step process for a successful Post Complete Response meeting request.

Video | Transcript | Slides (PDF - 109KB)

Requests for Reconsideration

This video describes what is new and what has changed in GDUFA II for Requests for Reconsideration.

Video | Transcript | Slides (PDF - 128KB)

Review Classification

Learn about review classification for ANDAs and the difference between standard versus priority review.

Webinar | Slides (PDF - 77KB)

Related Resources

GDUFA II Commitment Letter
	Generic Drug User Fee Amendments (GDUFA)
	GDUFA Glossary
	GDUFA Guidances and MaPPs
	GDUFA Implementation Activities

                                                                                  Content current as of:
      11/02/2017Generic Drug User Fee Amendments

          
                        GDUFA III Reauthorization
          Pre-ANDA Program
          ANDA Assessment Program
          Controlled Correspondence
          Drug Master File (DMF) Assessments
          Changes for Facilities
          User Fee Resource Management Program
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop